Niche radiopharma Public utility foundation focused on producing radioisotopes for diagnostic and therapeutic nuclear medicine, offering targeted opportunities in radiopharmaceutical supply chains and contract manufacturing for imaging and therapy agents.

Subsidiary growth IRE ELiT expands offerings with radiopharmaceutical derivatives for cancer treatment and palliative care, plus radiological monitoring and project development units, creating cross-sell opportunities for diagnostics, therapies, and regulatory services.

Regional footprint Operations tied to Belgian territory via radiological monitoring capabilities, suggesting a potential entry point for EU-based partnerships, regulatory-compliant supply deals, and Joint Activities in radiopharmacy and safety labs.

Tech and data leverage Utilizes SAP, PostgreSQL, Redis, Azure, and analytics tools, indicating readiness for integrated supplier management, data-driven quality control, and digital collaboration in production planning and regulatory reporting.

Financial and scale Revenue in the small-to-mid market range with a 201-500 employee base, signaling an opportunity for scalable, value-driven partnerships with mid-size radiopharma players and service providers seeking reliable isotope sourcing and specialized lab services.